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Summary. Patients with von Willebrand disease (VWD),
the most common inherited bleeding disorder, display
large variation in bleeding tendency, which is not
completely related to VWF levels. The cause of variability
in clinical expression is largely unknown. The effect of
plasma fibrinolytic capacity on bleeding tendency in
VWD patients has not been investigated. We hypothe-
sized that enhanced fibrinolysis may result in a more
severe bleeding phenotype. Therefore, we measured the
fibrinolytic potential in patients with moderate or severe
VWD to investigate the contribution of fibrinolysis to the
bleeding tendency. Fibrinolytic potential was measured
as plasma clot lysis time (CLT) with and without addition
of potato carboxypeptidase inhibitor (PCI) in 638
patients with moderate or severe VWD who partici-
pated in a nationwide multicentre cross-sectional study.
Bleeding severity was measured using the Bleeding Score
(BS).The CLTs were significantly longer, indicative of
hypofibrinolysis, in men compared to women with VWD
[106.2 (IQR 95.7–118.1) vs. 101.9 (IQR 92.8–114.0)
min]. The CLTs prolonged with increasing age. No
association was found between VWF or FVIII levels and
CLT, or between VWF or FVIII levels and CLT+PCI. No
association was observed for BS in a model with 10log-
transformed CLT, adjusted for age, gender, VWF:Act
and FVIII [b = 6.5 (95%CI )0.3 to 13.4)]. Our study
showed that the plasma fibrinolytic potential does not
influence bleeding tendency in VWD patients and there-
fore does not explain the variability in bleeding pheno-
type in VWD.
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Introduction
von Willebrand disease (VWD) is the most common
inherited bleeding disorder, caused by defects in or
reduced levels of von Willebrand factor (VWF) [1]. The
VWF plays a major role in primary haemostasis by
facilitating adhesion of platelets to the endothelium,
thereby initiating aggregation of platelets to form a
platelet plug. In addition, VWF is the carrier protein of
factor VIII (FVIII) [2].
In patients with VWD, VWF and FVIII levels largely
determine the bleeding tendency, however, the variation
in bleeding tendency between individuals with VWD is
not completely related to VWF levels [3]. Some patients
bleed excessively, whereas others with similar VWF
levels in plasma have only mild bleeding problems. Also
within families with similar mutations, large differences
in bleeding phenotype are observed [3]. The cause of
this variability in clinical expression of VWD is largely
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unknown. It has recently been shown that variability in
thrombin generation may lead to differences in bleeding
phenotype in VWD [4].
Another factor that may determine the variability in
clinical expression of VWD is the rate of fibrinolysis. The
effect of fibrinolysis on the bleeding tendency in VWD
patients has not yet been investigated. The fibrinolytic
system converts plasminogen into plasmin, which
degrades the insoluble fibrin clot into soluble fibrin
degradation products. Thrombin activatable fibrinolysis
inhibitor (TAFI) connects the coagulation cascade with
the fibrinolytic system. Upon high concentrations of
thrombin, TAFI is activated by thrombin and effectively
inhibits fibrinolysis by removing carboxyterminal lysine
residues from partially degraded fibrin, thereby dimin-
ishing the cofactor function of fibrin in plasminogen
activation [5].
Recent studies have indicated that the fibrinolytic
potential, measured by a clot lysis assay, show consid-
erable inter-individual variation [6]. This variability
may also influence the bleeding phenotype of VWD
individuals. In addition, in severe VWD patients the
fibrinolytic potential may be altered by strongly reduced
FVIII levels, leading to impaired thrombin generation
via the intrinsic feedback-loop and less TAFI activation.
Therefore, reduced FVIII levels in VWD not only have
an effect on coagulation but may also enhance fibrino-
lysis. Previous studies have already indicated that TAFI
levels and activation correlate with the fibrinolytic
potential in healthy individuals [7,8]. Patients with
enhanced fibrinolysis predominantly present with
mucocutaneous bleeding [9–11], such as menorrhagia,
epistaxis and gum bleeding. These bleeding symptoms
are also frequently observed in patients with VWD [12].
We hypothesized that differences in fibrinolytic
capacity may influence the bleeding tendency among
VWD patients, i.e. enhanced fibrinolysis may result in a
more severe bleeding phenotype. Therefore, we mea-
sured the fibrinolytic potential in a large cohort of
patients with moderate or severe VWD to investigate
the role of fibrinolysis in bleeding phenotype of VWD
patients.
Methods
Willebrand in the Netherlands study
We performed a nation-wide cross-sectional study
among patients with moderate and severe VWD in the
Netherlands, the ‘Willebrand in the Netherlands’ (WiN)
study. Patients were recruited at all 13 Haemophilia
Treatment Centres in the Netherlands.
We included patients diagnosed with type 1, type 2
and type 3 VWD who fulfilled both of the following
inclusion criteria: (i) haemorrhagic symptoms or a
family history of VWD; (ii) historically lowest levels
of VWF antigen (VWF:Ag) £30 U dL)1 and/or VWF
activity (VWF ristocetin cofactor activity (VWF:RCo)
£30 U dL)1 and/or factor (F)VIII:C £40 U dL)1, deter-
mined at the local Haemophilia Treatment Centre.
For the current analysis we included all patients, both
children and adults. Data were obtained between
October 2007 and October 2009. All participants, or
their parents, completed a questionnaire and a blood
sample was obtained. The Medical Ethical Committee
decided that in children blood could only be obtained if
for clinical purposes a blood sample was needed. The
Medical Ethical Committees at all participating centres
approved this study, and written informed consent was
obtained from all study participants and/or their
parents.
Definitions
Determination of type of VWD was based on the current
ISTH guidelines [13,14], using the laboratory parameters
determined at the local Hemophilia Treatment Cen-
ter. The severity of VWD was defined as proposed by
Federici [15]. Severe VWD was defined as the presence of
at least one of the following laboratory abnormalities:
VWF:Ag <10 U dL)1, and/or VWF:CB <10 U dL)1, and/
or VWF:RCo <10 U dL)1, and/or FVIII <20 U dL)1.
Moderate VWD was defined as VWF:Ag 10–30 U dL)1,
and/or VWF:CB 10–30 U dL)1, and/or VWF:RCo 10–
30 U dL)1, and/or FVIII 20–40 U dL)1 [15]. Children
were defined as study participants aged 0–16 years.
Laboratory measurements in VWD
Historic measured VWF and FVIII levels in the
Hemophilia Treatment Centers were used as inclusion
criteria for the WiN study, and patients with at least one
measurement of VWF below 30 U dL)1 or FVIII below
40 U dL)1 (for type 2N), respectively, were included.
All participants were asked to give blood for
re-evaluation of von Willebrand parameters.
Peripheral venous blood was collected in tubes
containing 3.2% (0.109 m) sodium citrate. Subsequently,
the tubes were centrifuged twice at 2200 · g for 10 min
at room temperature and finally the citrated platelet-poor
plasma (PPP) was aliquoted and stored at )80C.
Plasma levels of VWF:Ag, VWF collagen binding
(VWF:CB), VWF activity (VWF:Act) and FVIII were
measured centrally (Erasmus University Medical Cen-
ter, Rotterdam, The Netherlands). Briefly, VWF:Ag
level was measured with an in-house ELISA using a
polyclonal rabbit anti-human VWF antibody (Dako-
Cytomation, Glostrup, Denmark) for capturing and
HRP-conjugated anti-human VWF antibody (Dako-
Cytomation) for detecting. The VWF:CB level was
measured with an in-house ELISA using collagen type 1
for capturing and HRP-conjugated anti-human VWF
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antibody for detecting. The VWF:Act assay uses latex
particles coated with a monoclonal murine antibody
directed against the GpIba-binding domain of VWF.
These latex particles were incubated with the patient
plasma (Instrumentation Laboratory B.V, Breda, The
Netherlands) and agglutination of the particles, pro-
portionally to the GpIba-binding activity of VWF, was
measured (Sysmex CA-1500, TOA Medical Electronics,
Kobe, Japan). The FVIII:C was measured in a one-stage
clotting assay (TriniCLOT, Biomerieux, Marcy l’Etoile,
France) with FVIII-deficient plasma (Biopool, Umea,
Sweden).
Plasma fibrinolytic potential
The fibrinolytic potential of VWD patients was studied
using a plasma fibrinolytic potential assay [7,16,17].
Lysis of a tissue factor-induced clot by exogeneous
tissue-type plasminogen activator (t-PA) was studied
by monitoring changes in turbidity during clot forma-
tion and subsequent lysis as described previously [7].
Briefly, 70 lL of citrated PPP was added to 96 wells
plate (Falcon; BD Biosciences, Franklin Lakes, NJ,
USA) followed by 49 lL of assay buffer (25 mm
HEPES; 137 mm NaCl; 3.5 mm KCl; 1% BSA; pH
7.4). After mixing, 85 lL of the diluted plasma was
added to another 96 wells plate containing 15 lL
assay mixture. The assay mixture included: assay
buffer, tissue factor (Innovin, Dade Behring, Marburg,
Germany), CaCl2, t-PA (Actilyse, Boehringer Ingel-
heim, Ingelheim am Rhein, Germany), phospholipids
(Rossix, Mölndal, Sweden). Plasma samples were
measured both in absence and presence of potato
carboxypeptidase inhibitor (PCI), a potent inhibitor of
activated TAFI [18]. The inhibitory effect of TAFI on
the fibrinolytic potential is excluded by adding PCI.
The final concentrations in the plasma clot were 1000·
diluted tissue factor (Innovin), 17 mm CaCl2,
30 ng mL)1 t-PA, 10 lm phospholipids and 2· diluted
plasma. In the measurements with PCI, the final
concentration of PCI in the plasma clot was
30 lg mL)1. Finally, after mixing the diluted plasma
with the assay mixture (1400 rpm on a plate shaker
for 10 s), 50 lL paraffin oil (Merck, Darmstadt,
Germany) was added to the wells. The plate was then
immediately inserted into a 37C preheated microplate
reader (Biotek, Winooski, VT, USA). Optical density
was measured at 405 nm every minute for 300 min.
The time of the midpoint from the lowest to highest
optical density was used as a measure for clotting time,
while the time of the midpoint from highest to lowest
optical density was used as a measure for lysis time.
The clot lysis time (CLT) was calculated as the
difference between clotting and lysis time. A represen-
tative graph of the fibrinolytic potential assay (optical
density plotted against time) is shown in Fig. 1. The
intra- and inter-assay variation coefficients were 3.5%
and 6.5%, respectively.
In patients with type 3 VWD, low FVIII levels due to
an increased FVIII clearance, will theoretically lead to
less thrombin generation and subsequently to less TAFI
activation and more enhancement of fibrinolysis (short-
ened CLT). Clot lysis time ratio (CLT ratio) was defined
as CLT divided by CLT+PCI, thus CLT with TAFI
activity divided by CLT without TAFI activity. The
CLT ratio was measured to study the effect of TAFI per
type of VWD.
Bleeding severity
Bleeding severity was assessed using the Tosetto Bleed-
ing Score (BS) [3,19]. The BS systematically evaluates
bleeding symptoms, and accounts for both the number
and severity of the bleeding symptoms. The 12 bleeding
items are scored on a scale ranging from )1 to 4 points.
Higher scores reflect more severe/frequent bleeding. The
total for all 12 items results in a BS that can range from
)3 (no bleeding) to 45 (severe bleeding).
Fig. 1. A representative graph of the output
generated by the plasma fibrinolytic potential
assay. Clot lysis time (CLT) was calculated as the
difference between clotting and lysis time.
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For additional analysis, we also used a mucocutaneous
bleeding score (BS-mucocutaneous), which accounts for
six mucocutaneous bleeding symptoms (epistaxis,
bleeding from minor wounds, oral cavity bleeding,
gastrointestinal bleeding, bleeding after tooth extraction
and menorrhagia).
Statistical analysis
Data were analysed with two objectives. First, determi-
nants of CLT were assessed. The CLT presented a
skewed distribution to the right. Due to non-normal
distribution, the Mann–Whitney U and Kruskal–Wallis
tests were used to compare CLT between groups. We
used linear regression to model the associations between
CLT and its potential determinants. Because the distri-
bution of CLT is skewed, CLT was 10log-transformed.
Second, we investigated the association between CLT
and BS. Three linear regression models were built with
BS or BS-mucocutaneous as dependent variable and
10log-CLT, age, gender, FVIII and VWF:Act as the




In the Willebrand in the Netherlands (WiN) study, 806
patients with moderate to severe VWD were included.
Plasma was available for 687 VWD patients. Eighteen
VWD patients were excluded because of either preg-
nancy or treatment with desmopressin or FVIII/VWF
concentrate 3 days before blood samples were drawn.
In 31 VWD patients, no CLT could be determined as
the plasma clot did not reach the midpoint from
maximum turbidity to clear transition within 300 min.
These patients were excluded from subsequent analyses.
A flow chart of the study population is shown in Fig. 2.
Table 1 shows the characteristics of the WiN study
population. In total, for 638 patients both data on
bleeding phenotype and CLT were available; of these
61% were women. The majority of patients were
diagnosed as VWD type 1 (n = 372, 58%), type 2 was
diagnosed in 35% (n = 222), type 3 was diagnosed in
4% (n = 28) of the included patients, and 3% (n = 16)
of the patients remained non-classified. VWF:Ag,
VWF:CB, VWF:Act and FVIII levels were strongly
reduced in our cohort with VWD patients, see Table 1.
Median CLT of the study population was 102.5 min
[inter-quartile range (IQR) 92.3–114.0 min], median
CLT+PCI was 72.1 min (IQR 65.4–80.9 min).
An association between VWF or FVIII level and BS
was found. The median BS was 11 (95% CI 10–11) in
(n = 564) patients with VWF:Ag levels >10 IU dL)1 and
15 (13–17) in (n = 74) patients with VWF:Ag level
£10 IU dL)1. Patients with VWF:Act levels >10 IU dL)1
(n = 473) or FVIII:C levels >10 IU dL)1 (n = 605) had a
median BS of 10 (10–11) and 11 (10–12), respectively.
A median BS of 14 (13–15) and 18 (15–21) was observed
in patients with VWF:Act levels £10 IU dL)1 (n = 186)
or FVIII:C levels £10 IU dL)1 (n = 33).
Association between VWF and FVIII levels and CLT
No associations were found between VWF or FVIII level
and CLT, see Table 2. Patients in a subgroup with higher
FVIII level (>30 IU dL)1) had slightly higher CLTs,
although this difference was not statistically significant,
P for trend 0.097. No associations were found between
VWF or FVIII level and CLT+PCI, measuring CLT in the
absence of TAFI activity, see Table 2.
Fig. 2. Flow chart of the WiN study population.
Table 1. Characteristics of the WiN study population.
Total n = 638
Gender Females (n,%) 389 61%
Age Median, IQR 45 30–58
VWD type 1 (n,%) 372 58%





2 not specified 28
3 (n,%) 28 4%
Unspecified (n,%) 16 3%
VWF:Ag Median U dL)1, IQR 29 18–44
VWF:CB Median U dL)1, IQR 22 7–49
VWF:Act Median U dL)1, IQR 22 8–52
FVIII:C Median U dL)1, IQR 50 32–72
Blood group O n,% 382 60%
VWD severity Severe VWD (n,%) 253 40%
Moderate VWD (n,%) 385 60%
Bleeding Score Median, range 10 )1–35
CLT Median (min), IQR 102.5 92.3–114.0
CLT+PCI Median (min), IQR 72.1 65.4–80.9
IQR, interquartile range; PCI, potato carboxypeptidase inhibitor; VWD,
von Willebrand disease; VWF, von Willebrand factor; CLT, clot lysis time.
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Determinants of CLT in VWD patients
The CLTs were prolonged in men compared to women
with VWD [106.2 (IQR 95.7–118.1) vs. 101.9 (IQR
92.8–114.0) min, P = 0.008], see Table 3. In children no
gender difference was found [90.8 (IQR 85.3–98.0) vs.
90.4 (IQR 84.8–103.0) min, P = 0.600], for boys and
girls, respectively, see Fig. 3. The CLT steadily prolonged
with age, an increase in age of 10 years was associated
with an increase in CLT of 3.3 min (95% CI 2.3–4.4).
The CLTs of the children were significantly shorter
compared with adult VWD patients [90.6 (IQR 85.3–
100.5) vs. 103.7 (IQR 93.2–115.0) min, P < 0.001]. No
difference in CLT was found between patients with type
1, 2 and 3 VWD. However, a significant difference in
CLT+PCI (to exclude the effect of TAFI) between the
various types of VWD was observed, see Table 3.
Patients with type 3 VWD had prolonged CLTs com-
pared with VWD type 1 and type 2. Within the group of
patients with type 2 VWD, patients with subtype 2A had
the highest CLT (data not shown).
Association between CLT measured in presence and
absence of PCI
Correlation between CLT and CLT+PCI was highly
significant (r = 0.857, P < 0.001), indicating that VWD
patients with a high overall CLT also had a high basal,
TAFI-independent CLT. To study the contribution of
TAFI and TAFI activation on lysis time we measured
CLT ratios. In Fig. 4, the CLT ratios per type of VWD
are depicted. A significant higher CLT ratio was
observed in type 1 compared to type 2 and type 3
VWD patients [median CLT ratio in type 1 VWD 1.45
(IQR 1.37–1.52), type 2 VWD 1.39 (IQR 1.32–1.47),
type 3 VWD 1.36 (1.27–1.43), P < 0.001].
Effect of fibrinolysis on BS
For both BS and BS-mucocutaneous three models
were built to adjust for other factors that could
potentially affect the association between BS and
Table 2. Association between CLT and
VWF/FVIII levels.Levels* CLT (IQR) P for trend
 CLT+PCI (IQR) P for trend
VWF:Ag 0–10 100.3 (90.4–112.5) 0.122 72.5 (65.6–79.1) 0.222
10–20 99.5 (90.8–109.7) 71.0 (63.3–78.7)
20–30 101.5 (91.0–114.2) 71.0 (64.6–79.8)
>30 103.8 (94.7–117.6) 73.3 (66.3–82.8)
VWF:CB 0–10 102.4 (91.3–111.6) 0.316 72.2 (65.0–80.9) 0.822
10–20 103.9 (93.5–111.2) 72.4 (67.2–79.7)
20–30 96.6 (89.4–112.6) 71.0 (64.4–78.5)
>30 103.0 (93.6–117.7) 72.1 (65.2–82.2)
VWF:Act 0–10 100.4 (90.3–110.5) 0.121 71.0 (64.9–78.5) 0.421
10–20 103.2 (91.8–110.6) 72.5 (66.7–80.0)
20–30 103.5 (92.9–115.5) 72.0 (64.5–81.8)
>30 103.3 (93.4–117.9) 72.6 (65.9–82.8)
FVIII:C 0–10 101.9 (90.2–112.2) 0.097 74.6 (67.9–78.9) 0.132
10–20 102.5 (90.3–111.3) 71.7 (65.4–78.4)
20–30 98.5 (90.9–107.4) 68.7 (64.9–78.7)
>30 103.4 (92.9–115.0) 72.2 (65.3–82.1)
*In IU dL)1.
Clot lysis time and clot lysis time+PCI were 10log-transformed.
Table 3. Clot lysis time in subgroups of VWD patients.
N Median CLT IQR *P-value Median CLT+PCI IQR *P-value
Sex
Children Boys 35 90.8 85.3–98.0 0.600 66.4 62.2–74.4 0.771
Girls 26 90.4 84.8–103.0 68.4 60.4–74.1
Adults Males 214 106.2 95.7–118.1 0.008 71.7 65.7–81.5 0.379
Females 363 101.9 92.8–114.0 72.8 66.6–81.8
Age 0–16 61 90.6 85.3–100.5 <0.001 67.5 61.0–74.1 <0.001
16–40 200 99.4 90.9–108.5 70.0 63.6–78.1
41–60 244 105.1 93.1–122.4 73.3 65.4–83.6
61–86 133 107.0 99.0–117.3 75.4 68.4–83.7
Type VWD Type 1 372 101.0 91.5–112.6 0.259 70.4 63.9–78.9 <0.001
Type 2 221 104.2 94.2–114.5 74.5 68.3–82.0
Type 3 28 103.2 89.6–112.0 76.2 69.5–87.4
Blood group O 382 101.2 91.9–111.8 0.085 71.5 65.0–80.3 0.100
Non-O 247 104.0 93.0–115.0 73.4 65.9–81.6
IQR, interquartile range.
*Mann–Whitney U or Kruskal–Wallis test for differences between subgroups.
Bold values indicate significant P-values.
448 E. M. DE WEE et al.
Haemophilia (2012), 18, 444–451  2011 Blackwell Publishing Ltd
CLT, including age, gender, VWF:Act and FVIII. The
results are summarized in Table 4. An association was
found between both BS and BS-mucocutaneous
with 10log-transformed CLT [b = 9.6 (95% CI 2.8–
16.4), and b = 7.9 (95% CI 3.3–12.4), respectively].
However, for BS and CLT no significant association
was found after adjustment for age, gender, VWF:Act
and FVIII (b = 6.5, 95%CI )0.3 to 13.4), for
BS-mucocutaneous a small regression coefficient was
found (b = 5.3, 95% CI 0.72–10.0). After additional
stratification for type of VWD this association dis-
appeared (data not shown).
Discussion
We did not observe an association between the fibrino-
lytic potential, measured by a plasma-based clot lysis
assay, and bleeding tendency in our cohort of moderate
to severe VWD patients. Therefore, our hypothesis that
a higher fibrinolytic potential may increase the bleeding
tendency in VWD patients could not be confirmed in
this study.
In patients with VWD, a large variation in fibrinolytic
capacity was observed, which was irrespective of FVIII
and VWF level. The fibrinolysis assay we used is an
overall measure of the plasma fibrinolytic potential in
which the total balance of plasma proteins involved in
clot degradation determines the outcome, and a single
factor is only of limited importance [7]. The large
variability in CLT was also observed earlier in healthy
individuals [6,16,17].
We hypothesized that enhanced fibrinolysis might
result in a more severe bleeding tendency, leading to an
inverse relationship between CLT and bleeding pheno-
type, assessed by the Tosetto Bleeding Score. We studied
mucocutaneous bleeding separately, because of the high
fibrinolytic activity in mucosal tissue and the high
frequency of mucosal bleeding in patients with fibrino-
lysis abnormalities [20]. We found a weak, positive
association between CLT and BS, however, in adjusted
models this association disappeared. This is in line with
a previous study in haemophilia patients, in whom an
association between clot lysis and bleeding phenotype
could not be demonstrated [21].
An explanation for the fact that no association
between BS and CLT was found, might be that our
Fig. 4. Clot lysis time ratios in different types of VWD. CLT ratio is
defined as CLT (with TAFI activity) divided by CLT+PCI (without TAFI
activity). *P < 0.05. Bars represent the median CLT:CLT+PCI ratio.
Fig. 3. Clot lysis time per gender and age-group. Children had significantly
lower CLTs compared to all other age groups (Mann–Whitney test
P < 0.001). Only in patients aged 41–60 years a significantly different CLT
was found between men and women (Mann–Whitney test P = 0.006). Both
for men and women CLTs increased significantly with age (Kruskal–Wallis
test P < 0.001). Error bars: 95% CI.
Table 4. Linear regression models representing the effect of clot lysis time
on the Bleeding Score.
n = 638
BS BS mucocutaneous
b (95% CI) b (95% CI)
CLT
Model I 9.6 (2.8–16.4) 7.9 (3.3–12.4)
Model II 5.8 ()1.2–12.8) 5.4 (0.7–10.1)
Model III 6.5 ()0.3–13.4) 5.3 (0.7–10.0)
Model I: independent variable 10log-CLTs.
Model II: independent variables 10log-CLTs, age and gender.
Model III: independent variables 10log-CLTs, age, gender, VWF:Act and
FVIII.
b represents the increase in BS or BS mucocutaneous per min increase of
10log-CLT.
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cohort was strictly defined and only patients with
moderate or severe VWD i.e those who have a relatively
high BS were included. The selection of the study-group,
not including mild VWD patients may have masked the
effect of fibrinolysis on bleeding tendency. Mild VWD
patients have a larger variability in bleeding phenotype
and may be better suited to study the effect of
fibrinolysis on bleeding variability. Furthermore, we
studied bleeding phenotype by determining the BS in
our study [3]. We used the BS because it is a validated
method to determine bleeding phenotype in VWD
patients. The BS was originally developed by Tosetto
et al. to distinguish between type 1 VWD patients and
patients without VWD. This BS has not been used to
quantify bleeding symptoms in patients with disorders
of fibrinolysis.
The CLT was also measured in presence of PCI, an
inhibitor of activated TAFI, to study specifically the role
of TAFI. We hypothesized that very low FVIII levels in
severe VWD patients might influence the fibrinolytic
system because of less TAFI activation, which may in turn
lead to differences in bleeding phenotype. The fibrinolytic
potential measured in the presence of TAFI inhibitor
(CLT+PCI) was indeed increased (shortened CLT+PCI).
The anticipated effect of low FVIII activity and concom-
itant reduced TAFI activation on CLT is not reflected in
the clot lysis assay in our study (Table 2). Previous studies
showed that FVIII levels were not associated with CLTs
in healthy individuals [7]. Furthermore, it was shown
that addition of only 0.01 U dL)1 FVIII in severe
haemophilia A patients, who are completely lacking
FVIII, already resulted in maximal prolongation of CLT,
suggesting the effect of FVIII at fibrinolysis is maximal at
low concentration [22].
Although we did not find an association between the
global plasma fibrinolysis and bleeding tendency, future
studies should investigate whether or not the variation
in bleeding tendency in VWD might be partly related to
individual components of the fibrinolytic system. In the
global fibrinolysis assay that we used in this study,
exogenous t-PA was added, therefore effects of t-PA or
other fibrinolysis protein variations might be masked.
Other global fibrinolysis assays or measurement of
individual fibrinolysis proteins including a2-antiplas-
min, PAI-1 or TAFI levels may still be relevant in
understanding the variation in bleeding tendency in
VWD.
In conclusion, our study showed that the plasma
fibrinolytic potential does not influence bleeding ten-
dency in VWD patients and therefore does not explain
the variability in bleeding phenotype in VWD.
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